Multidrug-Resistant Tuberculosis in Europe, 2010–2011

Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Günther, Gunar, van Leth, Frank, Alexandru, Sofia, Altet, Neus, Avsar, Korkut, Bang, Didi, Barbuta, Raisa, Bothamley, Graham, Ciobanu, Ana, Crudu, Valeriu, Davilovits, Manfred, Dedicoat, Martin, Duarte, Raquel, Gualano, Gina, Kunst, Heinke, de Lange, Wiel, Leimane, Vaira, Magis-Escurra, Cecile, McLaughlin, Anne-Marie, Muylle, Inge, Polcová, Veronika, Pontali, Emanuele, Popa, Christina, Rumetshofer, Rudolf, Skrahina, Alena, Solodovnikova, Varvara, Spinu, Victor, Tiberi, Simon, Viiklepp, Piret, Lange, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344280/
https://www.ncbi.nlm.nih.gov/pubmed/25693485
http://dx.doi.org/10.3201/eid2103.141343
Descripción
Sumario:Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non–MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010–2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

Ejemplares similares